Time Course of Elevations in Plasma Olprinone Concentration during Pediatric Cardiac Surgery

Satoshi Kurokawa, Minoru Nomura

Department of Anesthesiology, Faculty of Medicine, Tokyo Women’s Medical University, Tokyo, Japan.

DOI: 10.4236/ojanes.2013.32020                

Abstract

Purpose: Little research has been reported to date on the usefulness of olprinone in pediatric cardiac surgery, and no standard pediatric infusion protocol is currently established. Our study sought to confirm that the regimen described herein rapidly achieves the requisite plasma olprinone concentrations. Methods: For the purposes of our study, we enrolled 13 patients: 7 biventricular repair candidates and 6 Fontan-type operation candidates. We administered a continuous infusion of olprinone to our study subjects at 0.3 μg/kg/min with no loading dose starting approximately 30 minutes (min) before weaning from cardiopulmonary bypass (CPB). We performed blood sampling at 15, 30, 45, 60, 90, and 120 min after the start of infusion and at the same elapsed intervals after separation from CPB. We measured plasma olprinone concentrations using ultra-fast liquid chromatography. Results: We observed effective plasma olpri-none concentrations (>20 ng/ml) at 30 min after weaning from CPB, or at 60 min after the start of infusion. Conclusion: We conclude that continuous olprinone infusion at 0.3 μg/kg/min without a loading dose initiated immediately after the release of aortic cross-clamping or immediately after the completion of all surgical procedures quickly and reliably achieves effective plasma concentrations.

Keywords

Olprinone; Phosphodiesterase-3 Inhibitor; Plasma Concentration; Pediatric Cardiac Surgery; Weaning from Cardio-Pulmonary Bypass

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	T. M. Hoffman, G. Wernovsky, A. M. Atz, T. J. Kulik, N. D. P. Nelson, A. C. Chang, et al., “Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children after Corrective Surgery for Congenital Heart Disease,” Circulation, Vol. 107, No. 7, 2003, pp. 996-1002. z doi:10.1161/01.CIR.0000051365.81920.28
[2]	Y. Orime, M. Shiono, H. Hata, S. Yagi, S. Tsukamoto, S. Kimura, et al., “Post-Operative Effects of Olprinone after Coronary Artery Bypass Grafting,” Annals of Thoracic and Cardiovascular Surgery, Vol. 4, No. 6, 1998, pp. 340- 346.
[3]	T. Arai, Y. Takano, S. Muzukami and I. Sato, “The Effect of Olprinone Administered after Cardiopulmonary Bypass during Open Heart Surgery, Evaluated by Its Plasma Concentrations and Hemodynamic Changes (in Japanese with English Abstract),” Masui (The Japanese Journal of Anesthesiology), Vol. 48, No. 10, 1999, pp. 1083-1090.
[4]	T. Arai, “Effects of Olprinone Hydrochroride after Coronary Artery Bypass Grafting (in Japanese with English Abstract),” Masui (The Japanese Journal of Anesthesiology), Vol. 53, No. 2, 2004, pp. 122-130.
[5]	M. Unoshima, H. Iwasaka, S. Hattori, T. Kitano and T. Noguchi, “Effects of Olprinone Hydrochloride on Hemodynamics and Respiratory Oxygenation in Patients after Cardiac Surgery (in Japanese with English Abstract),” Masui (The Japanese Journal of Anesthesiology), Vol. 46, No. 8, 1997, pp. 1053-1058.
[6]	T. Arai, K. Kamishima, T. Terauchi, Y. Enomoto, M. Shimazaki, H. Inoue, et al., “Effects of Olprinone Hydrochroride in Patients Undergoing Off-Pump Coronary Artery Bypass Grafting (in Japanese with English Abstract),” Masui (The Japanese Journal of Anesthesiology), Vol. 55, No. 2, 2006, pp. 158-163.
[7]	M. Itou, H. Okamoto, J. Suwa, T. Asou and S. Hoka, “Application of a PDE-3 Inhibitor, Olprinone, for Fast Track Pediatric Cardiac Surgery (in Japanese with English Abstract),” Masui (The Japanese Journal of Anesthesiology), Vol. 53, No. 3, 2004, pp. 258-263.
[8]	T. Iwasaki, Y. Toda, K. Shimizu, K. Suzuki, T. Kanazawa and K. Morita, “Hemodynamic Effects of Phosphodiesterase-3 Inhibitors, Olprinone and Milrinone after Open Heart Surgery in Child of Congenital Heart Disease,” Anesthesia & Analgesia, Vol. 106, No. S1, 2008, pp. 1- 128.
[9]	K. Sha, M. Iwata, M. Mori, Y. Motozu, N. Yonemoto, K. Kitaguchi, et al., “Evaluation of the Different Doses of Olprinone for Continuous Infusion after Cardiopulmonary Bypass for Coronary Artery Bypass Surgery (in Japanese with English Abstract),” Masui (The Japanese Journal of Anesthesiology), Vol. 52, No. 6, 2003, pp. 621-625.
[10]	J. M. Bailey, J. H. Levy, M. Kikura, F. Szlam and C. C. Hug Jr., “Pharmacokinetics of Intravenous Milrinone in Patients Undergoing Cardiac Surgery,” Anesthesiology, Vol. 81, No. 3, 1994, pp. 616-622. doi:10.1097/00000542-199409000-00014
[11]	J. M. Bailey, B. E. Miller, W. Lu, S. R. Tosone, K. R. Kanter and V. K. Tam, “The Pharmacokinetics of Milrinone in Pediatric Patients after Cardiac Surgery,” Anesthesiology, Vol. 90, No. 4, 1999, pp. 1012-1018. doi:10.1097/00000542-199904000-00014
[12]	C. Ramamoorthy, G. D. Anderson, G. D. Williams and A. M. Lynn, “Pharmacokinetics and Side Effects of Milrinone in Infants and Children after Open Heart Surgery,” Anesthesia & Analgesia, Vol. 86, No. 2, 1998, pp. 283- 289. doi:10.1097/00000539-199802000-00011